Abstract:Objective: Bladder cancer is one of the most prominent malignancies affecting the urinary tract, characterized by a poor prognosis. Our previous research has underscored the pivotal role of m6A methylation in the progression of bladder cancer. Nevertheless, the precise relationship between N6-methyladenosine (m6A) regulation of long non-coding RNA (lncRNA) and bladder cancer remains elusive. Methods: This study harnessed sequencing data and clinical records from 408 bladder cancer patients in the TCGA database. Employing R software, we conducted bioinformatics analysis to establish an m6A-lncRNA co-expression network. Analyzing the differences between high and low-risk groups, particularly at the immunological level, and subsequently investigating the primary regulatory factors of these lncRNA, validating the findings through experiments, and exploring their specific cellular functions. Results: We identified 50 m6A-related lncRNA with prognostic significance through univariate Cox regression analysis. In parallel, we employed a LASSO-Cox regression model to pinpoint 11 lncRNA and calculate risk scores for bladder cancer patients. Based on the median risk score, patients were categorized into low-risk and high-risk groups. The high-risk cohort exhibited notably lower survival rates than their low-risk counterparts. Further analysis pointed to RBM15 and METTL3 as potential master regulators of these m6A-lncRNA. Experimental findings also shed light on the upregulated expression of METTlL3 and RBM15 in bladder cancer, where they contributed to the malignant progression of tumors. The experimental findings demonstrated a significant upregulation of METTL3 and RBM15 in bladder cancer specimens, implicating their contributory role in the oncogenic progression. Knockdown of METTL3 and RBM15 resulted in a marked attenuation of tumor cell proliferation, invasion, and migration, which was concomitant with a downregulation in the cellular m6A methylation status. Moreover, these results revealed that RBM15 and METTL3 function in a synergistic capacity, positing their involvement in cancer promotion via the upregulation of m6A modifications in long non-coding RNAs. Additionally, this study successfully developed an N-methyl-N-nitrosourea (MNU)-induced rat model of in situ bladder carcinoma, confirming the elevated expression of RBM15 and METTL3, which paralleled the overexpression of m6A-related- lncRNAs observed in bladder cancer cell lines. This congruence underscores the potential utility of these molecular markers in in vivo models that mirror human malignancies. Conclusion: This study not only offers novel molecular targets,but also enriches the research on m6A modification in bladder cancer, thereby facilitating its clinical translation.

C-Myc/mettl3/linc01006 /LINC01006 Positive Feedback Loop Promotes Migration, Invasion and Proliferation of Non-Small Cell Lung Cancer

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2

METTL3‑mediated M6a Modification of Bcl‑2 Mrna Promotes Non‑small Cell Lung Cancer Progression

LINC00426, a Novel M6a-Regulated Long Non-Coding RNA, Induces EMT in Cervical Cancer by Binding to ZEB1

LINC00461/miR-4478/E2F1 Feedback Loop Promotes Non-Small Cell Lung Cancer Cell Proliferation and Migration.

LINC00426, a novel m 6 A-regulated long non-coding RNA, induces EMT in cervical cancer by binding to ZEB1

M6a Methyltransferase METTL3 Promotes Non-Small-cell Lung Carcinoma Progression by Inhibiting the RIG-I-MAVS Innate Immune Pathway

HNRNPA2B1-mediated m 6 A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis

HNRNPA2B1-mediated m<SUP>6</SUP>A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis

METTL3 facilitates the progression of cervical cancer by m6A modification-mediated up-regulation of NEK2

Enhancing m6A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer

M2 macrophage exosomal LINC01001 promotes non-small cell lung cancer development by affecting METTL3 and glycolysis pathway

The Long Noncoding RNA LINC00665 Facilitates c-Myc Transcriptional Activity via the miR-195-5p MYCBP Axis to Promote Progression of Lung Adenocarcinoma

METTL3-induced DLGAP1-AS2 promotes non-small cell lung cancer tumorigenesis through m6A/c-Myc-dependent aerobic glycolysis

METTL3 Modulates M6a Modification of CDC25B and Promotes Head and Neck Squamous Cell Carcinoma Malignant Progression

LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1

METTL3 Promotes the Growth and Invasion of Melanoma Cells by Regulating the Lncrna SNHG3/miR-330-5p Axis

N6-methyladenosine-induced METTL1 promotes tumor proliferation via CDK4

LINC00958-MYC positive feedback loop modulates resistance of head and neck squamous cell carcinoma cells to chemo- and radiotherapy in vitro.

LINC00680 Promotes the Progression of Non-Small Cell Lung Cancer and Functions as a Sponge of miR-410-3p to Enhance HMGB1 Expression